Immuron (IMRN) Current Deferred Revenue (2016 - 2025)

Immuron (IMRN) posted quarterly Current Deferred Revenue of $791391.0 for Q3 2025, up 5.39% quarter-over-quarter from $750920.1 in Q4 2024.

Immuron (IMRN) Current Deferred Revenue (2016 - 2025) Analysis & Trends

Immuron's Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $791391.0 for Q3 2025.

In Q3 2025, Current Deferred Revenue changed N/A year-over-year to $791391.0; the TTM figure through Sep 2025 stood at $791391.0 (changed N/A YoY), while the FY2025 annual figure was $791391.0, changed N/A from the prior year.
Current Deferred Revenue for Q3 2025 stood at $791391.0, up from $750920.1 in the prior quarter.
The five-year high for Current Deferred Revenue was $15.2 million in Q4 2022, with the low at $15784.6 in Q2 2021.
The 5-year median for Current Deferred Revenue is $432518.5 (2023), against an average of $3.1 million.
The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue sank 98.1% in 2021, then jumped 34713.31% in 2022.
Immuron's Current Deferred Revenue stood at $43771.8 in 2021, then surged by 34713.31% to $15.2 million in 2022, then slipped by 15.85% to $12.8 million in 2023, then slumped by 94.14% to $750920.1 in 2024, then gained by 5.39% to $791391.0 in 2025.
Business Quant data shows IMRN's Current Deferred Revenue at $791391.0 in Q3 2025, $750920.1 in Q4 2024, and $389617.3 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Immuron	6.75 Mn	6.73 Mn	-

Download Data